Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Forecasted to Earn FY2022 Earnings of ($3.97) Per Share

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMGet Rating) – HC Wainwright boosted their FY2022 earnings estimates for shares of Mirum Pharmaceuticals in a research report issued on Monday, November 14th. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of ($3.97) for the year, up from their previous forecast of ($4.18). HC Wainwright currently has a “Buy” rating and a $69.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($4.12) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2022 earnings at ($0.95) EPS, Q1 2023 earnings at ($0.90) EPS, Q2 2023 earnings at ($0.84) EPS, Q3 2023 earnings at ($0.79) EPS, Q4 2023 earnings at ($0.63) EPS, FY2023 earnings at ($3.15) EPS, FY2024 earnings at ($0.55) EPS and FY2025 earnings at $3.37 EPS.

Other analysts have also issued reports about the stock. Citigroup reduced their price objective on shares of Mirum Pharmaceuticals from $38.00 to $34.00 and set a “buy” rating for the company in a research note on Thursday, November 10th. Raymond James raised their price objective on shares of Mirum Pharmaceuticals from $75.00 to $88.00 and gave the company a “strong-buy” rating in a research note on Tuesday, October 25th.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM opened at $19.58 on Wednesday. The firm has a market cap of $721.91 million, a P/E ratio of -17.48 and a beta of 1.44. Mirum Pharmaceuticals has a fifty-two week low of $12.82 and a fifty-two week high of $30.55. The firm has a 50-day simple moving average of $21.45 and a two-hundred day simple moving average of $22.82.

Insider Activity

In other news, Director Niall O’donnell sold 32,109 shares of the firm’s stock in a transaction dated Monday, November 14th. The shares were sold at an average price of $19.60, for a total transaction of $629,336.40. Following the sale, the director now owns 1,714,888 shares of the company’s stock, valued at approximately $33,611,804.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 33.27% of the company’s stock.

Hedge Funds Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in MIRM. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Mirum Pharmaceuticals in the first quarter worth approximately $41,000. Victory Capital Management Inc. purchased a new position in shares of Mirum Pharmaceuticals in the first quarter worth approximately $1,087,000. AdvisorShares Investments LLC purchased a new position in shares of Mirum Pharmaceuticals in the first quarter worth approximately $288,000. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 110.5% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 53,301 shares of the company’s stock worth $1,174,000 after buying an additional 27,979 shares during the last quarter. Finally, Panagora Asset Management Inc. boosted its holdings in shares of Mirum Pharmaceuticals by 3.6% in the first quarter. Panagora Asset Management Inc. now owns 69,486 shares of the company’s stock worth $1,530,000 after buying an additional 2,427 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Mirum Pharmaceuticals Company Profile

(Get Rating)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

Further Reading

Earnings History and Estimates for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.